scispace - formally typeset
T

Thomas Lehmann

Researcher at University Hospital of Basel

Publications -  33
Citations -  1676

Thomas Lehmann is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Myeloproliferative neoplasm & Polycythemia vera. The author has an hindex of 11, co-authored 33 publications receiving 1476 citations. Previous affiliations of Thomas Lehmann include University of Basel.

Papers
More filters
Journal ArticleDOI

Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage.

TL;DR: TIs identified a considerable number of RBC concentrates whose temperatures may not be adequately reflected by the 30-minute rule and stressed the necessity of validation prior to implementation.
Journal ArticleDOI

Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG)

TL;DR: This work sought to further analyze the relationships between issues of intimacy (sexual desire and function), their relationships to MPN disease features, individual MPN symptom prevalence and severity, language, and overall quality of life among an international cohort of patients with MPNs.
Journal ArticleDOI

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

TL;DR: Thrombotic risk increases in anti-PF4/heparin IgG-positive PV reflecting potential implications and calling for larger, confirmatory cohorts.
Journal ArticleDOI

The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients

TL;DR: The Myelofibrosis Symptom Burden (MF-SB) : An International Phenotypic Cluster Analysis of 329 Patients shows clear trends in morbidity and mortality among patients diagnosed with MF.
Journal ArticleDOI

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

TL;DR: The results of this study suggest that patients with thrombocytopenia will benefit from aggressive symptomatic control, potentially from targeted agents.